34 unchanged sentences
Amendments to, and waivers from, the code of business conduct and ethics that apply to any director, executive officer or persons performing similar functions will be disclosed at the website address provided above and, to the extent required by applicable regulations, on a Current Report on Form 8-K filed with the SEC.
+Added: We have adopted an insider trading policy governing the purchase, sale and other dispositions of our securities by our directors, officers and employees that we believe is reasonably designed to promote compliance with insider trading laws, rules and regulations, and any applicable listing standards.
+Added: A copy of our insider trading policy is filed as Exhibit 19 to this Annual Report on Form 10-K.
Executive Compensation
22 unchanged sentences
Form of Warrant
+Added: Form of Pre-Funded Warrant
+Added: Form of Common Warrant
Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
19 unchanged sentences
and Angel Pharmaceuticals US Inc.
+Added: Sub-Sublease agreement, dated as of October 22, 2024, by and between Corvus Pharmaceuticals, Inc.
+Added: and NewLimit, Inc.
2014 Equity Incentive Plan.
1 unchanged sentence
Amendment to the 2014 Equity Incentive Plan, dated July 24, 2015.
−Removed: Amendment to the 2014 Equity Incentive Plan, dated September 14, 2015.
−Removed: Form of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan.
Incorporated by Reference
Exhibit Description
+Added: Amendment to the 2014 Equity Incentive Plan, dated September 14, 2015.
+Added: Form of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan.
Form of Restricted Stock Purchase Right Grant Notice and Restricted Stock Purchase Agreement under the 2014 Equity Incentive Plan.
14 unchanged sentences
and William B.
+Added: Employment Agreement, dated as of February 2, 2024 by and between Corvus Pharmaceuticals, Inc.
+Added: and Jeffrey S.
Corvus Pharmaceuticals, Inc.
10 unchanged sentences
Framework Agreement, dated as of October 5, 2020, by and between Corvus Hong Kong Limited, Jiaxing Puissance Angel Equity Investment Partnership (Limited Partnership) and AP BIOTECH DEVELOPMENT CORP.
−Removed: Open Market Sale Agreement, dated March 28, 2023, by and between Corvus Pharmaceuticals, Inc.
+Added: Open Market Sale Agreement, dated August 6, 2024, by and between Corvus Pharmaceuticals, Inc.
and Jefferies LLC.
+Added: Incorporated by Reference
+Added: Exhibit Description
+Added: Securities Purchase Agreement, dated May 1, 2024, between the Company and the Investors.
+Added: Insider Trading Policy
List of subsidiaries
2 unchanged sentences
Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Incorporated by Reference
−Removed: Exhibit Description
Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
47 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.